Q3 2019 Investor Presentation
Big data analysis drives insights for
treatment of central sleep apnea
Patients with treatment-emergent central sleep apnea (CSA)
are two times more likely to terminate therapy
• Opportunity to rethink conventional therapeutic options
.
• Minimize risk of therapy termination through early diagnosis
•
Regularly monitor patients to support adherence to treatment
CHEST
Journal
Analysis of ~200k CSA patients
100
50
22% increase in adherence
CMS adherence on CPAP
prior to switching
62.7%
CMS adherence
after switching to ASV
76.6%
•
Switching from therapy
CPAP to ASV improved
relative adherence by
22%
Patients who switched
from CPAP to ASV had
fewer apneas and
hyponeas during sleep
© 2019 ResMed I Q3 2019 Investor Presentation | 49
ResMedView entire presentation